Sera Labs offers 1,500 recombinant proteins

Published: 1-Jun-2010
Research & Development

Including cytokines, growth factors, chemokines, hormones, enzymes and viral antigens

Sera Laboratories International, a UK-based serum specialist, has developed more than 1,500 recombinant proteins for a variety of species including human, mouse, rat, porcine, bovine and chicken. The collection includes cytokines, growth factors, chemokines, hormones, enzymes and viral antigens.

Sera Lab’s recombinant proteins are mainly derived from bacterial systems and also include mammalian, yeast, insect and plant sources. All are rigorously tested to ensure excellent quality and biological activity.

With headquarters and storage in Haywards Heath, West Sussex and a cell culture research facility in France, Sera Lab offers a complete range of animal-based research products from a variety of origins. The company supplies laboratories in more than 30 countries worldwide, either directly or through distributors.

See more

You may also like

Research & Development

Med Uni Graz researchers present a new approach to targeted therapy for leukaemia

Read more
Acute myeloid leukaemia (AML) is a cancer of the haematopoietic cells that causes the uncontrolled proliferation of certain immature blood cells

Trending Articles

  1. GlaxoSmithKline and Oxford BioTherapeutics partner to advance antibody-based therapeutics for cancer The collaboration leverages OBT's proprietary OGAP-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targets
  2. Biotech Fluidics AB At Biotech Fluidics, our aim is to help you make your analytical work more effective and reliable.
  3. PLL Therapeutics opens New Zealand subsidiary to accelerate ALS clinical research in Asia-Pacific The new entity will support Phase II ALS patient recruitment in New Zealand (where incidence rates exceed the global average) and expand PLL Therapeutics’ footprint in the Asia-Pacific neurodegenerative disease research landscape
  4. Groundbreaking research suggests plastic waste could be used to make anti-cancer drugs A discovery made by the University of St Andrews has revealed a way to turn ordinary household plastic waste into the building block for anti-cancer treatments
  5. Lindus Health and Quotient Sciences team up to accelerate drug development process The pair will provide biotech and pharma sponsors with enhanced patient recruitment for early-stage clinical trials and a direct path from first-in-human to proof-of-concept trials

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

You may also like

Research & Development

Med Uni Graz researchers present a new approach to targeted therapy for leukaemia

Acute myeloid leukaemia (AML) is a cancer of the haematopoietic cells that causes the uncontrolled proliferation of certain immature blood cells
Manufacturing

When science meets security: the future of small molecule outsourcing

Looking across 2025 and into 2026, chemical and pharmaceutical manufacturing is navigating a period of rapid transition, with trends emerging that will influence competitiveness for years to come
Research & Development

Research shows that Pepaxti is effective in high-risk myeloma

Oncopeptides announces new research demonstrating that Pepaxti (melflufen) maintains its anti-myeloma activity in patients with high-risk genetic features, including deletion 17p (del(17p)) and TP53 mutations
Research & Development

Biologics at a turning point: complexity, AI and the road to 2026

Despite rapid change, the growing complexity of biologics and the rise of AI-driven design are reinforcing the increasing need for deep scientific expertise and innovation leadership, says Campbell Bunce (CB), Chief Scientific Officer at Abzena
Research & Development

CHITOSE and FUJIFILM Biosciences form strategic alliance to drive global innovation and biopharmaceutical manufacturing

Collaboration formed to accelerate biopharmaceutical manufacturing, combining high-performing CHO-MK cells and GMP-manufactured culture media
Research & Development

Groundbreaking research suggests plastic waste could be used to make anti-cancer drugs

A discovery made by the University of St Andrews has revealed a way to turn ordinary household plastic waste into the building block for anti-cancer treatments
Research & Development

Lindus Health and Quotient Sciences team up to accelerate drug development process

The pair will provide biotech and pharma sponsors with enhanced patient recruitment for early-stage clinical trials and a direct path from first-in-human to proof-of-concept trials
Subscribe now